K003445
p.1/3

DEC - 1 2000

# Fresenius Medical Care

**Fresenius Viral Retentive Transducer Protector for Hemodialysis**
**"Special" 510(k) Premarket Notification**
**Summary of Safety and Effectiveness**

This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of SMDA 1990.

**A. Submitter's Information:**

| | |
|---|---|
| Name: | Fresenius Medical Care North America |
| Address: | 95 Hayden Ave<br>Two Ledgemont Center<br>Lexington, MA 02420 |
| Phone: | 1-781-402-9068 |
| Fax: | (781) 402-9082 |
| Contact Person: | Arthur Eilinsfeld, Director of Regulatory Affairs |
| Date of Preparation: | 29 November, 2000 |

**B. Device Name:**

| | |
|---|---|
| Trade Name: | Fresenius Viral Retentive Transducer Protector for for Hemodialysis |
| Common/Usual Name: | Transducer Protector |
| Classification Name: | Protector, Transducer, Dialysis |

**C. Predicate Device Name:**

The Fresenius Viral Retentive Transducer Protector for Hemodialysis is identical to the Borla transducer protector with viral claim cleared for use with the Combilines™ Blood Tubing Sets, under the following premarket notification:

- #K000702 (6/7/00).

**D. Device Description/Indications for Use:**

This hydrophobic filter helps prevent the passage of viruses, bacteria, and other particulate matter, as well as preventing the flow of fluids to the hemodialysis machine at pressures below 600 mmHg.

# Fresenius Medical Care

**Fresenius Viral Retentive Transducer Protector for Hemodialysis**
**"Special" 510(k) Premarket Notification**
## Summary of Safety and Effectiveness

**E. Substantial Equivalence:**

**1. Is the product a device?**

**YES** - The transducer protectors are devices pursuant to 21 CFR §201 [321] (h).

**2. Does the new device have the same intended use?**

**YES** – The intended use for the Fresenius Viral Retentive Transducer Protector for Hemodialysis is equivalent to that for the Borla transducer protector with viral claim cleared under #K000702 (6/7/00), and is as follows:

**Intended Use for the Borla Transducer Protector (#K000702)**

*Transducer Protectors are single use, disposable prescription devices intended for use as protective devices for pressure monitors on hemodialysis machines, as well as to help protect the sterility of the blood tubing fluid pathway. The filter helps prevent cross-contamination by viruses, bacteria, and other particulate matter while preventing the flow of fluids to the hemodialysis machine's pressure transducer.*

**Intended Use for the Fresenius Viral Retentive Transducer Protector for Hemodialysis**

*This hydrophobic filter helps prevent the passage of viruses, bacteria, and other particulate matter, as well as preventing the flow of fluids to the hemodialysis machine at pressures below 600 mmHg.*

**3. Does the device have technological characteristics that raise new types of safety or effectiveness questions?**

**NO** – The Fresenius Viral Retentive Transducer Protector for Hemodialysis is identical to the Borla transducer protectors with viral claim cleared under #K000702 (6/7/00) and raises no new types of safety or effectiveness questions.

# Fresenius Medical Care

**Fresenius Viral Retentive Transducer Protector for Hemodialysis**
**"Special" 510(k) Premarket Notification**
## Summary of Safety and Effectiveness

**4. Does descriptive or performance information demonstrate equivalence?**

**YES** – Fresenius Medical Care North America believes that the information provided in this submission clearly describes the Viral Retentive Transducer Protector for Hemodialysis and demonstrates that it is substantially equivalent to the Borla transducer protector with viral claim cleared under #K000702 (6/7/00).

**F. Safety Summary**

The Fresenius Viral Retentive Transducer Protector for Hemodialysis is substantially equivalent in construction, design, materials, and intended use to the Borla Transducer Protector with viral claim cleared in #K000702. In addition, testing of the Fresenius Viral Retentive Transducer Protector for Hemodialysis indicates that the device is safe and effective for its intended use.

**G. General Safety and Effectiveness Concerns**

The Fresenius Viral Retentive Transducer Protector for Hemodialysis labeling includes a package insert, which describes the device's indications for use, cautions and warnings that should be observed when using the device, as well as the general operating instructions. This information promotes safe and effective use of the device.

Arthur Eilinsfeld
Director of Regulatory Affairs

11/29/00
Date

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

DEC - 1 2000

Mr. Arthur Eilinsfeld
Director of Regulatory Affairs
Fresenius Medical Care – North America
Two Ledgemont Center
95 Hayden Avenue
LEXINGTON MA 02420-9192

Re: K003445
Fresenius Viral Retentive Transducer Protector
for Hemodialysis
Dated: November 2, 2000
Received: November 6, 2000
Regulatory Class: II
21 CFR §876.5820/Procode: 78 FIB

Dear Mr. Eilinsfeld:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Daniel G. Schultz, M.D.
Captain, USPHS
Acting Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure (s)

# Fresenius Medical Care

**Fresenius Viral Retentive Transducer Protector for Hemodialysis**
**"Special" 510(k) Premarket Notification**

## Indications for Use Statement

**Device Name:**

Fresenius Viral Retentive Transducer Protector for Hemodialysis

**Indications for Use:**

*This hydrophobic filter helps prevent the passage of viruses, bacteria, and other particulate matter, as well as preventing the flow of fluids to the hemodialysis machine at pressures below 600 mmHg.*

**PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED**

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-The-Counter Use
(Per 21 CFR 801.109)

David C. Seymour
(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
510(k) Number K003445